We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca’s FluMist has missed two flu seasons in the U.S. due to efficacy problems, and now a group of pediatric experts have recommended injected vaccines over the nasal option for the upcoming season.